参考文献/References:
[1]Dixon SJ,Lemberg KM,Lamprecht MR,et al.Ferroptosis: an iron-dependent form of nonapoptotic cell death[J].Cell,2012,149(5):1060-1072.[2]Xie Y,Hou W,Song X,et al.Ferroptosis: process and function[J].Cell Death Differ,2016,23(3):369-379.[3]Hassannia B,Vandenabeele P,Vanden Berghe T.Targeting Ferroptosis to Iron Out Cancer[J].Cancer Cell,2019,35(6):830-849.[4]Gao M,Monian P,Quadri N,et al.Glutaminolysis and Transferrin Regulate Ferroptosis[J].Mol Cell,2015,59(2):298-308.[5]Mancias JD,Wang X,Gygi SP,et al.Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy[J].Nature,2014,509(7498):105-109.[6]Lee H,Zandkarimi F,Zhang Y,et al.Energy-stress-mediated AMPK activation inhibits ferroptosis[J].Nat Cell Biol,2020,22(2):225-234.[7]Jiang X,Stockwell BR,Conrad M.Ferroptosis: mechanisms, biology and role in disease[J].Nat Rev Mol Cell Biol,2021,22(4):266-282.[8]Wang Y,Gao W,Shi X,et al.Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin[J].Nature,2017,547(7661):99-103.[9]Bayir H,Dixon SJ,Tyurina YY,et al.Ferroptotic mechanisms and therapeutic targeting of iron metabolism and lipid peroxidation in the kidney[J].Nat Rev Nephrol,2023,19(5):315-336.[10]Dixon SJ,Patel DN,Welsch M,et al.Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis[J].Elife,2014,3:e02523.[11]Sun X,Ou Z,Chen R,et al.Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells[J].Hepatology,2016,63(1):173-184.[12]Rojo de la Vega M,Chapman E,Zhang DD.NRF2 and the Hallmarks of Cancer[J].Cancer Cell,2018,34(1):21-43.[13]Doll S,Freitas FP,Shah R,et al.FSP1 is a glutathione-independent ferroptosis suppressor[J].Nature,2019,575(7784):693-698.[14]Soula M,Weber RA,Zilka O,et al.Metabolic determinants of cancer cell sensitivity to canonical ferroptosis inducers[J].Nat Chem Biol,2020,16(12):1351-1360.[15]Ou Y,Wang SJ,Li D,et al.Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses[J].Proc Natl Acad Sci U S A,2016,113(44):E6806-E6812.[16]Torti SV,Torti FM.Winning the war with iron[J].Nat Nanotechnol,2019,14(6):499-500.[17]Kerk SA,Papagiannakopoulos T,Shah YM,et al.Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment[J].Nat Rev Cancer,2021,21(8):510-525.[18]Zhang Y,Tan H,Daniels JD,et al.Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model[J].Cell Chem Biol,2019,26(5):623-633.e9.[19]Nakamura T,Hipp C,Santos Dias Mour?觔o A,et al.Phase separation of FSP1 promotes ferroptosis[J].Nature,2023,619(7969):371-377.[20]Zhu G,Murshed A,Li H,et al.O-GlcNAcylation enhances sensitivity to RSL3-induced ferroptosis via the YAP/TFRC pathway in liver cancer[J].Cell Death Discov,2021,7(1):83.[21]Mirhadi S,Zhang W,Pham NA,et al.Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non-Small Cell Lung Cancer[J].Mol Cancer Res,2023,21(1):36-50.[22]Yao F,Deng Y,Zhao Y,et al.A targetable LIFR-NF-κB-LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis[J].Nat Commun,2021,12(1):7333.[23]Sun X,Niu X,Chen R,et al.Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis[J].Hepatology,2016,64(2):488-500.[24]Zheng Y,Wang Y,Lu Z,et al.PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti-PD-1 Immunotherapy[J].Adv Sci (Weinh),2023,10(29):e2301928.[25]Zhao Y,Li M,Yao X,et al.HCAR1/MCT1 Regulates Tumor Ferroptosis through the Lactate-Mediated AMPK-SCD1 Activity and Its Therapeutic Implications[J].Cell Rep,2020,33(10):108487.[26]Wang K,Zhang Z,Tsai HI,et al.Branched-chain amino acid aminotransferase 2 regulates ferroptotic cell death in cancer cells[J].Cell Death Differ,2021,28(4):1222-1236.[27]Li JT,Yin M,Wang D,et al.BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma[J].Nat Cell Biol,2020,22(2):167-174.[28]Meng F,Xiao Y,Ji Y,et al.An open-like conformation of the sigma-1 receptor reveals its ligand entry pathway[J].Nat Commun,2022,13(1):1267.[29]Xu D,Li X,Shao F,et al.The protein kinase activity of fructokinase A specifies the antioxidant responses of tumor cells by phosphorylating p62[J].Sci Adv,2019,5(4):eaav4570.[30]Yang F,Li J,Deng H,et al.GSTZ1-1 Deficiency Activates NRF2/IGF1R Axis in HCC via Accumulation of Oncometabolite Succinylacetone[J].EMBO J,2019,38(15):e101964.[31]Li J,Wang Q,Yang Y,et al.GSTZ1 deficiency promotes hepatocellular carcinoma proliferation via activation of the KEAP1/NRF2 pathway[J].J Exp Clin Cancer Res,2019,38(1):438.[32]Knudsen ES,Knudsen KE.Tailoring to RB: tumour suppressor status and therapeutic response[J].Nat Rev Cancer,2008,8(9):714-724.[33]Manning AL,Dyson NJ.RB: mitotic implications of a tumour suppressor[J].Nat Rev Cancer,2012,12(3):220-226.[34]Orso F,Quirico L,Dettori D,et al.Role of miRNAs in tumor and endothelial cell interactions during tumor progression[J].Semin Cancer Biol,2020,60:214-224.[35]Gao R,Kalathur RKR,Coto-Llerena M,et al.YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis[J].EMBO Mol Med,2021,13(12):e14351.[36]Sun J,Zhou C,Zhao Y,et al.Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation[J].Redox Biol,2021,41:101942.[37]Bai T,Lei P,Zhou H,et al.Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells[J].J Cell Mol Med,2019,23(11):7349-7359.[38]Bai T,Wang S,Zhao Y,et al.Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells[J].Biochem Biophys Res Commun,2017,491(4):919-925.[39]Wang Q,Bin C,Xue Q,et al.GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis[J].Cell Death Dis,2021,12(5):426.[40]Li ZJ,Dai HQ,Huang XW,et al.Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma[J].Acta Pharmacol Sin,2021,42(2):301-310.[41]Lippmann J,Petri K,Fulda S,et al.Redox Modulation and Induction of Ferroptosis as a New Therapeutic Strategy in Hepatocellular Carcinoma[J].Transl Oncol,2020,13(8):100785.[42]Chen GQ,Benthani FA,Wu J,et al.Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis[J].Cell Death Differ,2020,27(1):242-254.[43]Lin PL,Tang HH,Wu SY,et al.Saponin Formosanin C-induced Ferritinophagy and Ferroptosis in Human Hepatocellular Carcinoma Cells[J].Antioxidants (Basel),2020,9(8):682.[44]Jin M,Shi C,Li T,et al.Solasonine promotes ferroptosis of hepatoma carcinoma cells via glutathione peroxidase 4-induced destruction of the glutathione redox system[J].Biomed Pharmacother,2020,129:110282.[45]Chang WT,Bow YD,Fu PJ,et al.A Marine Terpenoid, Heteronemin, Induces Both the Apoptosis and Ferroptosis of Hepatocellular Carcinoma Cells and Involves the ROS and MAPK Pathways[J].Oxid Med Cell Longev,2021,2021:7689045.[46]Xiong Y,Xiao C,Li Z,et al.Engineering nanomedicine for glutathione depletion-augmented cancer therapy[J].Chem Soc Rev,2021,50(10):6013-6041.[47]Du J,Wan Z,Wang C,et al.Designer exosomes for targeted and efficient ferroptosis induction in cancer via chemo-photodynamic therapy[J].Theranostics,2021,11(17):8185-8196.[48]Deng T,Hu B,Jin C,et al.A novel ferroptosis phenotype-related clinical-molecular prognostic signature for hepatocellular carcinoma[J].J Cell Mol Med,2021,25(14):6618-6633.[49]Liu Z,Wang L,Liu L,et al.The Identification and Validation of Two Heterogenous Subtypes and a Risk Signature Based on Ferroptosis in Hepatocellular Carcinoma[J].Front Oncol,2021,11:619242.[50]Liang JY,Wang DS,Lin HC,et al.A Novel Ferroptosis-related Gene Signature for Overall Survival Prediction in Patients with Hepatocellular Carcinoma[J].Int J Biol Sci,2020,16(13):2430-2441.[51]Du X,Zhang Y.Integrated Analysis of Immunity- and Ferroptosis-Related Biomarker Signatures to Improve the Prognosis Prediction of Hepatocellular Carcinoma[J].Front Genet,2020,11:614888.[52]Gao L,Xue J,Liu X,et al.A scoring model based on ferroptosis genes for prognosis and immunotherapy response prediction and tumor microenvironment evaluation in liver hepatocellular carcinoma[J].Aging (Albany NY),2021,13(22):24866-24881.
相似文献/References:
[1]王利娜,赵雪梅,徐云霞,等.磁共振扩散张量成像在肝细胞癌及
肝转移瘤鉴别诊断价值研究[J].医学信息,2018,31(09):12.[doi:10.3969/j.issn.1006-1959.2018.09.004]
WANG Li-na,ZHAO Xue-mei,XU Yun-xia,et al.Diagnostic Value of Magnetic Resonance Diffusion Tensor Imaging in Hepatocellular Carcinoma and Liver Metastases[J].Journal of Medical Information,2018,31(02):12.[doi:10.3969/j.issn.1006-1959.2018.09.004]
[2]刘 冰,杨 帅,费锡斌,等.GPC-3联合CK-19免疫组化检测在肝细胞癌诊断及鉴别诊断中的应用[J].医学信息,2019,32(23):169.[doi:10.3969/j.issn.1006-1959.2019.23.054]
LIU Bing,YANG Shuai,FEI Xi-bin,et al.Application of GPC-3 Combined with CK-19 Immunohistochemical Detection in Diagnosis and Differential Diagnosis of Hepatocellular Carcinoma[J].Journal of Medical Information,2019,32(02):169.[doi:10.3969/j.issn.1006-1959.2019.23.054]
[3]刘丽丽.CLCVP对肝细胞癌行腹腔镜肝叶切除手术相关指标及肝门阻断时间的影响[J].医学信息,2020,33(19):88.[doi:10.3969/j.issn.1006-1959.2020.19.025]
LIU Li-li.The Effect of CLCVP on the Operation-related Indexes and Port Occlusion Time in Patients with Hepatocellular Carcinoma Undergoing Laparoscopic Lobectomy[J].Journal of Medical Information,2020,33(02):88.[doi:10.3969/j.issn.1006-1959.2020.19.025]
[4]孙莹莹,龚先琼.中药单体治疗肝细胞癌的研究[J].医学信息,2021,34(09):33.[doi:10.3969/j.issn.1006-1959.2021.09.008]
SUN Ying-ying,GONG Xian-qiong.Study on the Treatment of Hepatocellular Carcinoma with Chinese Medicine Monomer[J].Journal of Medical Information,2021,34(02):33.[doi:10.3969/j.issn.1006-1959.2021.09.008]
[5]张祥鑫,董星星,耿 涛,等.基于与铁死亡相关基因的肺腺癌的新型预后模型构建[J].医学信息,2021,34(15):96.[doi:10.3969/j.issn.1006-1959.2021.15.025]
ZHANG Xiang-xin,DONG Xing-xing,GENG Tao,et al.Construction of A Novel Prognostic Model of Lung Adenocarcinoma Based on Genes Related to Iron Death[J].Journal of Medical Information,2021,34(02):96.[doi:10.3969/j.issn.1006-1959.2021.15.025]
[6]林思其,张泽鑫,夏睿琪,等.三种miRNA对肝癌预后预测的生物信息学分析模型[J].医学信息,2022,35(03):81.[doi:10.3969/j.issn.1006-1959.2022.03.019]
LIN Si-qi,ZHANG Ze-xin,XIA Rui-qi,et al.A Model of Three miRNA on the Prognosis Prediction of Hepatocellular Carcinomaby Bioinformatics Analysis[J].Journal of Medical Information,2022,35(02):81.[doi:10.3969/j.issn.1006-1959.2022.03.019]
[7]李一鸣,陈文翔,王 禹,等.肝癌预后模型的构建及其在免疫治疗中的作用研究[J].医学信息,2022,35(04):68.[doi:10.3969/j.issn.1006-1959.2022.04.018]
LI Yi-ming,CHEN Wen-xiang,WANG Yu,et al.The Construction of a Prognostic Model for Hepatocellular Carcinomaand its Role in Immunotherapy[J].Journal of Medical Information,2022,35(02):68.[doi:10.3969/j.issn.1006-1959.2022.04.018]
[8]王永霞,朱会芳,王明永,等.铁死亡在乳腺癌演进及治疗中的作用[J].医学信息,2022,35(05):1.[doi:10.3969/j.issn.1006-1959.2022.05.001]
WANG Yong-xia,ZHU Hui-fang,WANG Ming-Yong,et al.The Role of Ferroptosis in the Progression and Treatment of Breast Cancer[J].Journal of Medical Information,2022,35(02):1.[doi:10.3969/j.issn.1006-1959.2022.05.001]
[9]徐帅帅,高 斌.TACE与阿帕替尼联合治疗中晚期肝细胞癌的疗效及安全性分析[J].医学信息,2022,35(06):116.[doi:10.3969/j.issn.1006-1959.2022.06.028]
XU Shuai-shuai,GAO Bin.Analysis of the Efficacy and Safety of TACE Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma[J].Journal of Medical Information,2022,35(02):116.[doi:10.3969/j.issn.1006-1959.2022.06.028]
[10]李文华,许传斌,崔景景,等.基于治疗前MR-T2WI影像组学特征预测肝细胞癌射频消融术后早期复发的价值[J].医学信息,2022,35(18):39.[doi:10.3969/j.issn.1006-1959.2022.18.009]
LI Wen-hua,XU Chuan-bin,CUI Jing-jing,et al.The Value of Predicting Early Recurrence of Hepatocellular Carcinoma After Radiofrequency Ablation Based on Pre-treatment MR-T2WI Radiomics Features[J].Journal of Medical Information,2022,35(02):39.[doi:10.3969/j.issn.1006-1959.2022.18.009]